News articles about ChemoCentryx (NASDAQ:CCXI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ChemoCentryx earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.0565983016576 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- ChemoCentryx, Inc. (CCXI) stock price moves 40.56% up oppose to an average of last 200 Days (thestocksnews.com)
- Utah Retirement Systems Has Boosted Its Johnson & Johnson (JNJ) Stake; Chemocentryx (CCXI) Sentiment Is 1.3 (mtastar.com)
- ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting (finance.yahoo.com)
- Healthcare Stock in Focus: ChemoCentryx, Inc. (CCXI) (stocksgeeks.com)
- ChemoCentryx (CCXI) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
Several equities research analysts have issued reports on CCXI shares. BidaskClub upgraded shares of ChemoCentryx from a “sell” rating to a “hold” rating in a research note on Wednesday, March 14th. JPMorgan Chase reiterated an “overweight” rating and issued a $16.00 price target (up previously from $13.00) on shares of ChemoCentryx in a research note on Tuesday, March 13th. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, March 14th. Finally, ValuEngine raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Wednesday, March 14th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $15.00.
Shares of CCXI traded down $0.27 during trading hours on Thursday, hitting $11.86. 154,473 shares of the stock were exchanged, compared to its average volume of 296,492. ChemoCentryx has a fifty-two week low of $5.42 and a fifty-two week high of $15.08. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $606.03, a PE ratio of 32.94 and a beta of 1.58.
ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $1.02. The company had revenue of $56.30 million for the quarter, compared to the consensus estimate of $9.03 million. sell-side analysts anticipate that ChemoCentryx will post -1.18 EPS for the current fiscal year.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.